Evaluation of Lipid-Lowering Effects of Atorvastatin on Obese Patients Attending A Tertiary Healthcare Facility

Main Article Content

M. O. Ajulo
H.O. Ajulo
O. K. Agbo

Abstract

Introduction: Hyperlipidemia is a major cause of atherosclerosis and atherosclerosis-associated conditions, such as coronary heart disease (CHD), ischemic cerebrovascular disease (CVD), and peripheral vascular disease.
This is a progressive observational study which involved five obese participants on atorvastatin 10 mg daily and five obese participants who were not on atorvastatin who served as control group. A 3 ml blood sample was collected from the participants at recruitment and the participants were followed up after 30 days with another blood collection. The participants on atorvastatin had been adherent to drug before blood collection. The control participants were not taking any drug which lower serum cholesterol. The obtained blood samples were analysed in the laboratory for lipid profile parameters such as total cholesterol (TC), triglyceride (TG), high density lipoprotein (HDL), low density lipoprotein (LDL) and very low density lipoprotein (VLDL) by using TC, HDL and TG kits made by Randox. The results showed that the follow-up participants on atorvastatin had lipid profile of TC, TG, HDL, LDL and VLDL as 5.14±0.87 mmol/l, 1.72±0.32 mmol/l, 1.12±0.23 mmol/l, 3.24±0.79 mmol/l and 0.77±0.12 mmol/l respectively. The results for the follow-up control participants showed that TC, TG, HDL, LDL and VLDL were 4.76±0.76 mmol/l, 1.52±0.55 mmol/l, 1.15±0.15 mmol/l, 2.92±0.75 mmol/l and 0.68±0.25 mmol/l respectively. Comparison of the lipid profile of participants on atorvastatin and the control group showed that there was no significant variation in LDL (p= 0.435) at first phase and LDL (p= 0.523) at second phase respectively. There was no significant variation in reduction of LDL between the participants on atorvastatin and the control participants.

Downloads

Download data is not yet available.

Article Details

How to Cite
Ajulo , M. O., Ajulo , H., & Agbo , O. K. (2020). Evaluation of Lipid-Lowering Effects of Atorvastatin on Obese Patients Attending A Tertiary Healthcare Facility. Nigerian Journal of Pharmaceutical and Applied Science Research, 8(1), 24–31. Retrieved from http://mail.nijophasr.net/index.php/nijophasr/article/view/269
Section
Articles
Author Biographies

M. O. Ajulo

Department of Clinical Pharmacy and Biopharmacy, Faculty of Pharmacy, University of Uyo, Uyo, Akwa-Ibom State. Nigeria.

H.O. Ajulo

Department of Animal Science, Faculty of Agriculture, University of Uyo, Akwa-Ibom state. Nigeria.

References

Abhimanyu G and Vinaya S (2007). Update on dyslipidemia. Journal of Clinical Endocrinology and Metabolism, 92: 1581-1589.

Adams SP, Tsang M and Wright JM (2015). Atorvastatin for lowering lipids. Cochrane Database of Systematic Reviews, Issue 3. DOI: 10.1002/14651858.

Chan JM, Rimm EB, Colditz GA, Stampfer MJ and Willett WC (1994). Obesity, fat distribution, and weight gain as risk factors for clinical diabetes in men. Diabetes Care,17: 961-969.

Fernandez ML, Jones JJ, Ackerman D, Barona J, Calle M, Comperatore MV, Kim J, Anderseen C, Leite JO, Volek JS, Mcintosh M, Kalynych C, Najm W and Lerman H (2010). Low HDL cholesterol is associated with increased atherogenic lipoproteins and insulin resistance in women classified with metabolic syndrome. Nutr Res Pract, 4(6): 492–498. doi: 10.4162/nrp.2010.4.6.492

Gelber RP, Gaziano JM, Orav EJ, Manson JE, Burning JE and Kurt T (2008). Measures of obesity and cardiovascular riskamong men and women. Journal of the American College of Cardiology, 52(8):605?615.

Heart Protection Study Collaborative Group (2004). Effects of cholesterol-lowering with simvastatin on stroke and other major vascular events in 20,536 people with cerebrovascular disease or other high-risk conditions. Lancet, 363:757-767.

Heart Protection Study Collaborative Group (2002). MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet, 360: 7-22.

Heart Protection Study Collaborative Group (2003). MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: A randomised placebo-controlled trial. Lancet, 36: 2005-2016.

Law MR, Wald NJ and Rudnicka AR (2003). Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: Systematic review and meta-analysis. British Medical Journal, 326:1423

Mannu GS, Zaman MJS, Gupta A, Rehman HU and Myint PK (2013). Evidence of Lifestyle Modification in the Management of Hypercholesterolemia. Current Cardiology Reviews, 9: 1-13. doi:1875-6557/13.

Mardolkar M (2017). Body Mass Index (BMI) Data Analysis and Classification. IJCSMC, 6(2): 8 – 16.

McCarron Da, Oparil S, Chait A, Haynes RB, Kris-Etherton P, Stern JS, Resnick LM, Clark S, Morris CD, Hatton DC, Metz JA, McMahon M, Holcomb S, Snyder JW and PI-Sunyer FX (1997). Nutritional management of cardiovascular risk factors: A randomized clinical trial. Arch Intern Med 157(2): 169-177.

Moon JC and Bogle RG (2006). Switching statin: Using generic simvastatin as first line could save £2 billion over 5 years in England. BMJ, 332:1344–1345.

National Heart, Lung and Blood Institute (2012). Health Information for the Public. www.nhlbi.nih.gov. Received on October 21, 2018.

National Health and Medical Research Council (2016). Clinical Practice Guidelines for the Management of Overweight and Obesity in Adults, Adolescents and Children in Australia. www.nhmrc.gov.au. Received on October 23, 2018

Pulgaron ER (2013). Childhood obesity: A review of increased risk for physical and psychological comorbidities.ClinTher. 35(1): A18–A32. doi:10.1016/j.clinthera.2012.12.014.

Scandinavian Simvastatin Survival Study (1994). Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease. The Scandinavian Simvastatin Survival Study (4S). Lancet, 344:1383-1389.

Seidell JC (2010). Waist circumference and waist/hip ratio in relation to all?cause mortality,

cancer and sleep apnea. European Journal of Clinical Nutrition, 64(1):35?41.

Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, MacFarlane PW, McKillop JH, Packard CJ (1995).; West of Scotland Coronary Prevention Study Group Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. The New England Journal of Medicine, 333:1301-1307.

Stein EA, Lane M, Laskarzewski P (1998). Comparison of statins in hypertriglyceridemia. Am J Cardiol, 81: 66B-69B.

The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group (1998). Prevention of cardiovascular events and death with pravastatin in patients with coronary heart diseases and a broad range of initial cholesterol levels. The New England Journal of Medicine 339: 1349-1357.

Wadhera RK, Steen DL, Khan I, Giugliano RP and Foody JM (2015). A review of low-density lipoprotein cholesterol, treatment strategies and its impact on cardiovascular diseases mobidity and mortality. Journal of Clinical lipidology, 10(3):472-489. doi.org/10.1016/j.jacl.2015.11.010

World Health Organization (2016). Obesity and overweight- Fact sheet. Available at http://www.who.int/mediacentre/factsheets/fs311/en/ Retrieved November 2016.